FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
Rituxan News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

7/28/13

 

We are remodeling this Rituxan News Channel & the other 11 MS Drug Treatment Channels at the top of our Home Page!

  ALL 12 MS DRUG CHANNELS WILL BE COMPLETED ON OR BEFORE SEPTEMBER 1ST!    

Plus: Pardon our construction while we add Columnists to the MS News Channel for the 1st time!  


                                                                                                                           

7/18/13

 

TEST



4/19/10

 

AAN: Rituximab Eyed for Secondary Progressive MS

(Posted By: Josi Creek)

Targeting B cells implicated in progressive multiple sclerosis with rituximab (Rituxan) therapy might help patients diagnosed with the disease, according to data from a small study reported here.

"This study shows that rituximab could be an effective treatment in a subgroup of patients with secondary progressive multiple sclerosis," Carolina Ionete, MD, of the University of Massachusetts Medical School in Worcester, wrote in a poster presentation abstract for the annual meeting of the American Academy of Neurology.

To read the entire story, click HERE


4/14/10

 

"Update..about me becoming immune to Tysabri-He said that Rituxan worked as well as tysabri-I take infusions every 6 months"

(Posted By: Josi Creek)

Hi Stan!! I just wanted to give you an update on my situation. I sent you a message about me becoming immune to Tysabri a few weeks ago.

I went to my neuro yesterday. My MRI showed some new lesions, but no active ones (YAY)!

I am starting Rituxan at the beginning of April. I'm excited and nervous!

Thanks to everyone for their well wishes and words of encouragement!

I'm happy that my insurance agreed to pay for it without having to threaten to sue them or anything since it's not FDA approved for multiple sclerosis treatment.

When I went to the doctor on Monday, they only tested me for hepatitis since Rituxan treatment can lead to hepatitis virus reactivation.

He said that he thought Rituxan was a very good drug and worked just as well as tysabri.

I have to take two infusions every 6 months. I have to be admitted to the hospital for the very first one on April 8th and I have to come back for a second infusion on April 22nd which they will do through out patient.

After the 22nd, I'll be done for the next 6 months

To see comments left for Jessica, click HERE

CLICK HERE TO READ 1000'S OF OTHER STORIES ABOUT OUR 2,700 Facebook FRIENDS LIKE JESSICA

3/30/10

 

23 PERSONAL RITUXAN STORIES....with 100's of Tips & Comments from our 2,700 Facebook Friends & 3,300 MySpace Friends

3/27/10

 

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials





Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

Abstract

Objective. To evaluate the longterm safety of rituximab in clinical trials in patients with rheumatoid arthritis (RA).

Methods. Pooled analysis of safety data, including adverse events (AE) and infections, from patients treated with rituximab in combination with methotrexate in a global clinical trial program.

Results. A total of 2578 patients with RA received at least 1 course of rituximab. Safety analyses were based on 5013 patient-years of rituximab exposure. The most frequent AE was infusion-related reactions (25% of patients during the first infusion of Course 1). Less than 1% of infusion-related reactions were considered serious. Rates of AE and serious AE (SAE; 17.85 events/100 patient-yrs, 95% CI 16.72, 19.06) were stable following each course. The overall serious infection rate was 4.31/100 patient-years (95% CI 3.77, 4.92). Infections and serious infections over time remained stable across 5 courses at 4–6 events/100 patient-years. Compared with other patients with RA and with the general US population, there was no increased risk of malignancy.

Conclusion. In this longterm safety update in RA clinical trial patients, rituximab remained well tolerated over multiple courses. SAE and infections remained stable over time and by treatment course.

In patients with RA treated with rituximab, the longterm safety profile in selected clinical trial populations was consistent with observations from placebo-controlled clinical trials. Over 5 courses of rituximab treatment, serious adverse events, including serious infection and infusion reactions, did not increase over time.